While current immunotherapies targeting PD-1/PD-L1 and CTLA-4 have shown remarkable success in certain cancers [124,125], their efficacy remains limited by immunosuppressive tumor microenvironments and the “cold tumor” phenotype characterized by poor T cell infiltration [126,127]. This evidence concerns the gene CTLA4 and neoplasm.